Aging Clinical and Experimental Research has published a systematic review of population-based studies in which Makovski and colleagues examine the role of multimorbidity and frailty during the COVID-19 pandemic. The review synthesizes what was known in the early years of the pandemic about how multiple chronic conditions and frailty influence the risk of COVID-19-related outcomes.
Drawing on extensive searches in PubMed, Embase, the WHO COVID-19 Global Literature database, and PsycINFO, the authors screened 9,701 titles/abstracts and 267 full texts. Ultimately, 14 studies on multimorbidity and 5 on frailty were included, all using population-representative samples and validated measurement tools. The review considers both the etiological role (risk of infection and early outcomes) and the prognostic role (short- and long-term outcomes among infected individuals).
The findings consistently show that a higher burden of disease and greater frailty are associated with poorer SARS-CoV-2-related outcomes, primarily increased mortality. This was reflected in associations with the number of chronic conditions, the Charlson Comorbidity Index, specific disease combinations, and validated frailty scores. The available studies focused mainly on the first pandemic waves, where short-term outcomes were most thoroughly documented.
The authors highlight the need for further research that accounts for virus variants, repeated exposure, and vaccination, to better understand how the associations between multimorbidity, frailty, and COVID-19 outcomes may have evolved over time.
The full article is available at: https://doi.org/10.1007/s40520-023-02685-4

